Related Experiment Video
Updated: Jul 4, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
[Resistance to antiplatelet substances--a real clinical problem]
Tobias Geisler1, Meinrad Gawaz
1Abteilung für Kardiologie und Kreislauferkrankungen, Medizinische Klinik III, Klinikum der Eberhard-Karls-Universität Tübingen, Tübingen. tobias.geisler@med.uni-tuebingen.de
Herz
|June 27, 2008
Summary
Dual antiplatelet therapy with aspirin and clopidogrel is crucial for cardiovascular patients. Low response to these drugs, known as aspirin and clopidogrel resistance, increases atherothrombotic event risk.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Context:
- Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for cardiovascular risk patients.
- Coronary interventions carry risks of thrombotic complications, including stent thrombosis, particularly with drug-eluting stents.
- Individual response to antiplatelet therapy is increasingly recognized as critical for patient outcomes.
Purpose:
- To review the clinical relevance of resistance to aspirin and clopidogrel.
- To explore the multifactorial causes of antiplatelet resistance.
- To discuss alternative treatment options and the potential of guided antiplatelet therapy.
Summary:
- Resistance to aspirin and clopidogrel is a significant issue, linked to factors like nonadherence, patient demographics, acute coronary syndromes, and genetic variations.
- Point-of-care platelet function tests are emerging tools, but standardization challenges hinder widespread adoption.
- Personalized antiplatelet strategies guided by platelet function analysis show promise for improving platelet inhibition.
Impact:
- Understanding antiplatelet resistance is key to mitigating atherothrombotic events in high-risk cardiovascular patients.
- Further studies are needed to confirm if guided antiplatelet therapy improves clinical outcomes.
- This review highlights the importance of individualized treatment approaches in antiplatelet therapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...